# Revolution Medicines Shares Rise About 6% After Q3 Results Beat

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/49667
Published: 2026-11-06T00:31:32.000Z
Updated: 2026-11-06T00:31:32.000Z
Section: Business

> The company reaffirmed its 2026 GAAP operating expense range of $2.1 billion to $2.2 billion and posted a $1.90 per-share loss.

Revolution Medicines shares climbed about 6% in after-hours trading Wednesday, Nov. 4, after the oncology drug developer posted third-quarter results that topped expectations for both revenue and earnings.

The company reaffirmed its 2026 forecast for generally accepted accounting principles (GAAP) operating expenses of $2.1 billion to $2.2 billion. Its GAAP loss was $1.90 per share in the third quarter.